Thyroid nodules grow because of a combination of hormonal signals, nutritional gaps, genetic changes, and metabolic conditions that push thyroid cells to multiply faster than normal. About half of adults over 60 have at least one nodule, and most are benign. But understanding what drives their growth helps you make sense of monitoring plans and know which factors you can actually influence.
How TSH Drives Thyroid Cell Growth
The thyroid-stimulating hormone (TSH) your pituitary gland releases is the single biggest controller of thyroid cell function and growth. TSH binds to receptors on thyroid cells and tells them to produce hormones, but it also signals them to multiply. When TSH stays elevated over time, it causes the thyroid tissue to enlarge through a combination of individual cells getting bigger and new cells forming. This is the basic engine behind most nodule growth.
In some nodules, a genetic glitch in the TSH receptor or its signaling pathway locks the “grow” signal in the on position permanently. These somatic mutations cause a single clone of cells to keep expanding on its own, independent of how much TSH the brain is actually sending. The result is what’s called a toxic adenoma: a nodule that grows autonomously and often starts overproducing thyroid hormone.
Iodine Deficiency and Nodule Formation
Iodine is the raw material your thyroid needs to make hormones. When you don’t get enough, the gland can’t keep up with demand, so your pituitary compensates by pumping out more TSH. That sustained TSH stimulation has a direct growth-promoting effect on thyroid tissue, pushing it through a predictable sequence: general enlargement, then focal areas of overgrowth, then distinct nodules, and in some cases, nodules that begin functioning independently.
Populations with low iodine intake have significantly higher rates of thyroid nodules and goiter. Research in iodine-deficient regions of Portugal found median urinary iodine levels well below the 150 micrograms per liter threshold considered adequate, and nodular thyroid disease was the dominant thyroid disorder. Low iodine also shifts the types of thyroid cancer that develop, favoring more aggressive forms. In most developed countries, iodized salt has reduced this risk substantially, but mild deficiency still occurs, particularly in pregnant women whose iodine requirements increase.
Inflammation From Autoimmune Thyroid Disease
Hashimoto’s thyroiditis, the most common autoimmune thyroid condition, creates a chronic inflammatory environment in the gland. Immune cells infiltrate the thyroid tissue, damage follicular cells, and trigger ongoing repair cycles. A study tracking children and adolescents with Hashimoto’s found that the severity of thyroid inflammation on ultrasound and the level of thyroid peroxidase antibodies (a marker of autoimmune activity) both predicted the appearance of new nodules. The researchers concluded that the inflammatory state itself likely favors nodule formation.
Interestingly, nodules that were already present at diagnosis tended to stay relatively stable in size during follow-up, with only slight volume changes in either direction. But nodules that developed later, during the course of the disease, showed progressive growth even when patients were taking thyroid hormone replacement. This suggests that ongoing inflammation continues to create conditions for new nodule development, though it doesn’t necessarily accelerate the growth of existing ones.
Insulin Resistance and Metabolic Syndrome
High circulating insulin levels act as a growth signal for thyroid cells. Insulin itself stimulates cell proliferation, and it also increases levels of free insulin-like growth factor 1 (IGF-1), a potent driver of tissue growth. Both insulin receptors and IGF-1 receptors are present on thyroid follicular cells, and they play an active role in cell regulation and proliferation.
People with type 2 diabetes and insulin resistance have higher rates of thyroid nodules, and the connection appears to be dose-dependent: the more insulin resistant you are, the greater the proliferative stimulus on your thyroid. This is one reason obesity and metabolic syndrome show up as risk factors for nodule growth in population studies. It also means that improving insulin sensitivity through weight management and physical activity may reduce one of the signals pushing thyroid cells to multiply.
Estrogen and Pregnancy
Women develop thyroid nodules far more often than men, and estrogen is a major reason. Estrogen modifies thyroid function in several ways: it increases iodine clearance from the body, raises the demand for thyroid hormone production, and directly promotes thyroid cell growth. Both lab studies and animal models have confirmed that estrogen stimulates the growth of normal thyroid cells and cells from existing nodules.
Pregnancy amplifies all of these effects. Rising estrogen and human chorionic gonadotropin (hCG) both interfere with thyroid volume regulation and promote nodule development. Clinical evidence consistently shows that pregnancy has a promoting effect on thyroid size and nodule formation. Women who go through multiple pregnancies accumulate more exposure to these growth signals, which partly explains why thyroid nodules become increasingly common in women through their reproductive years and beyond.
Radiation Exposure
Radiation to the head, neck, or chest, particularly during childhood, is a well-established cause of thyroid nodules that can appear decades later. The latency period depends heavily on the dose. People exposed to low-dose radiation (common in older medical treatments for acne, tonsils, or an enlarged thymus) developed thyroid tumors an average of 37 years later. Those exposed to medium or high doses, such as from cancer treatment, developed nodules sooner, with median latency periods of 12 and 7.5 years respectively.
At lower doses, benign nodules tended to appear before malignant ones. At medium doses, the pattern reversed: malignant tumors took longer to develop, appearing at a median of 28 years versus 8 years for benign growths. The practical takeaway is that radiation-related nodules can show up many years or even decades after exposure, which is why doctors ask about your radiation history when evaluating a thyroid nodule.
Genetic Mutations That Fuel Growth
Some nodules grow because of acquired mutations in the DNA of individual thyroid cells. These aren’t inherited; they develop spontaneously over a lifetime. The most significant is the BRAF V600E mutation, found in roughly 45% of papillary thyroid cancers. This mutation is associated with more aggressive tumor behavior, including growth beyond the thyroid capsule, spread to lymph nodes, and higher rates of recurrence.
Other mutations linked to nodule growth include RAS mutations, RET/PTC rearrangements, and PAX8/PPARγ gene fusions. Each of these disrupts normal cell growth controls in slightly different ways, but the common thread is that they give affected cells a proliferative advantage over their neighbors, allowing a single clone to expand into a detectable nodule. The specific mutation present can influence both how fast a nodule grows and whether it’s likely to be cancerous.
Age and Cumulative Exposure
Thyroid nodules become more common with every decade of life. A large Korean study of over 72,000 people found nodules on ultrasound in 34% of the overall population, rising to 55% in those over 70. Among centenarians, 74% had at least one nodule, with women affected more often than men (78% versus 58%). A U.S. study of more than 6,000 patients found that the average number of nodules one centimeter or larger increased from 1.55 in people aged 20 to 29 up to 2.21 in those 70 and older.
The accumulation reflects decades of exposure to all the growth signals described above: TSH stimulation, metabolic factors, hormonal influences, and random genetic mutations that pile up over time. However, aging doesn’t necessarily mean faster growth. A prospective study following nearly 1,000 patients with benign nodules for five years found that being 60 or older was actually associated with half the risk of nodule growth compared to being under 45.
Does Growth Mean Cancer?
A growing nodule understandably raises concerns about malignancy, but the relationship between size and cancer risk is not what most people expect. Research from a tertiary care center found that the highest cancer risk was actually in nodules under 2 centimeters, where 64.8% were malignant in their study population. For nodules 2 to 3 centimeters, the cancer rate dropped to 17.6%. At 3 to 4 centimeters it was 10.6%, and at 4 centimeters or larger, just 7%.
This means that a nodule getting bigger does not automatically increase the likelihood it’s cancerous. The relationship is nonlinear, with a threshold around 2 centimeters. Beyond that size, continued growth is more often driven by benign processes like fluid accumulation, cystic degeneration, or ongoing hormonal stimulation rather than malignant proliferation. Nodules found incidentally on PET scans are an exception: up to one-third of those turn out to be cancerous regardless of size, because the scan picks up metabolically active tissue.